|
|
|
Volumn 2, Issue 2, 2004, Pages 97-104
|
|
New developments in the treatment of esophageal cancer.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DNA TOPOISOMERASE (ATP HYDROLYSING);
DRUG DERIVATIVE;
IRINOTECAN;
TUMOR PROTEIN;
ADENOCARCINOMA;
ADJUVANT THERAPY;
BRACHYTHERAPY;
DISEASE MANAGEMENT;
DRUG ANTAGONISM;
DRUG DELIVERY SYSTEM;
ESOPHAGUS RESECTION;
ESOPHAGUS TUMOR;
FORECASTING;
HUMAN;
LYMPHADENECTOMY;
METHODOLOGY;
MULTIMODALITY CANCER THERAPY;
PROGNOSIS;
RADIATION DOSE;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
ADENOCARCINOMA;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BRACHYTHERAPY;
CAMPTOTHECIN;
COMBINED MODALITY THERAPY;
DISEASE MANAGEMENT;
DNA TOPOISOMERASES, TYPE II;
DRUG DELIVERY SYSTEMS;
ESOPHAGEAL NEOPLASMS;
ESOPHAGECTOMY;
FORECASTING;
HUMANS;
LYMPH NODE EXCISION;
NEOADJUVANT THERAPY;
NEOPLASM PROTEINS;
PROGNOSIS;
RADIOTHERAPY DOSAGE;
RANDOMIZED CONTROLLED TRIALS;
|
|
EID: 34547530895
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (92)
|
